Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[How to measure glycemic instability?].

J L Selam1

  • 1Service de Diabétologie, Hôtel-Dieu, 1, Place du Parvis Notre-Dame, 75181 Paris, France. Jean-Louis.Selam@wanadoo.fr

Diabetes & Metabolism
|May 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclic relationships between diabetic nephropathy and cardiovascular risk factors.

Metabolic syndrome and related disorders·2008
Same author

Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study.

Diabetes & metabolism·2006
Same author

[Inhaled insulin, new perspective for insulin therapy].

Revue medicale de Liege·2005
Same author

Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience.

Diabetes & metabolism·2004
Same author

Effects of dipeptide administration on hypoglycaemic counterregulation in type 1 diabetes.

Diabetes & metabolism·2003
Same author

[How I explore...glycemic kinetics by continuous glucose monitoring].

Revue medicale de Liege·2003
Same journal

Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.

Diabetes & metabolism·2026
Same journal

Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors.

Diabetes & metabolism·2026
Same journal

Two faces of autoimmune hyperinsulinemia: contrasting type B insulin resistance syndrome and exogenous insulin antibody syndrome.

Diabetes & metabolism·2026
Same journal

CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

Diabetes & metabolism·2026
Same journal

Persistent burden and management gaps of hypoglycemia in pediatric type 1 diabetes: insights from the Epi-GLUREDIA Study.

Diabetes & metabolism·2026
Same journal

Blood oxygen saturation and its associations with autonomic and peripheral neuropathy in diabetes.

Diabetes & metabolism·2026
See all related articles

Glycemic instability in type 1 diabetes can be quantified using various indices. The Low Blood Glucose Index (LBGI) and Mean of Daily Differences (MODD) offer valuable insights into hypoglycemia and day-to-day glucose control.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Context:

  • Glycemic instability is common in type 1 diabetes (T1D), ranging in severity.
  • Brittle diabetes is characterized by recurrent ketoacidosis or severe hypoglycemia.
  • Accurate quantification of glycemic variability is crucial for effective T1D management.

Purpose:

  • To review and discuss various indices for quantifying glycemic instability in T1D.
  • To highlight the utility of indices like MAGE, LBGI, and MODD in assessing glucose variability.
  • To emphasize the importance of these indices for clinical decision-making and patient monitoring.

Summary:

  • Standard deviation and value distribution offer limited insights into glycemic variability.
  • The MAGE index effectively measures the amplitude of glucose excursions.

Related Experiment Videos

  • The novel Low Blood Glucose Index (LBGI) quantifies hypoglycemia frequency and severity, potentially serving as a key indicator.
  • The Mean of Daily Differences (MODD) assesses day-to-day glucose value reproducibility.

    • Impact:

    • These indices can be readily integrated into glucose meters with large memory capacities.
    • Improved quantification of glycemic variability can lead to more personalized T1D treatment strategies.
    • Enhanced monitoring tools can empower patients and clinicians to better manage T1D, reducing complications.